Effects of Lactocaseibacillus paracasei subsp. paracasei NTU 101 on gut microbiota: a randomized, double‐blind, placebo‐controlled clinical study

Abstract

AbstractBACKGROUNDLactocaseibacillus paracasei subsp. paracasei NTU 101 (NTU101) is a well‐known commercial probiotic with multiple health beneficial effects. In this study, the gut microbiota modulation effect of an NTU 101 product, Vigiis 101‐LAB, on healthy human was investigated in a randomized, double‐blind, placebo‐controlled human trial.RESULTSVigiis 101‐LAB significantly modulated human gut microbiota at fourth and sixth weeks of trial (anosim analysis, P = 0.001). It also significantly improved peristalsis (P = 0.003) and shortened defecation interval of subjects. The shift of gut microbiota is significantly fit with defecation interval (P = 0.009) and stool shape (P = 0.001) of subjects.CONCLUSIONOur results suggest that Vigiis 101‐LAB promotes human intestinal health with improvement of peristalsis and fecal quality. The gut modulation effects of Vigiis 101‐LAB subsequently raised the abundance of vitamin B7, vitamin K, pyrimidine and purine biosynthesis pathways. Vigiis 101‐LAB may promote peristalsis via purinergic pathway and possibly conferring prophylactic benefits against irritable bowel syndrome with constipation. © 2024 Society of Chemical Industry.